Psychopharmacology bulletin最新文献

{"title":"A Case of Clozapine Induced Mania-Like Symptoms in the Treatment of Schizophrenia.","authors":"Alyssa H Sze, Akhil S Pola, Amanda G Smith, Jay Vora, Michael P Greenage","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clozapine is an atypical antipsychotic and is the drug of choice for treatment-resistant schizophrenia. Unlike other atypical antipsychotics which are known to occasionally cause symptoms of mania or hypomania, clozapine has been shown to be effective at symptom reduction during manic episodes in treatment-resistant bipolar disorder and is generally well tolerated in those severe mood disorders. To our knowledge, there is only one other reported case of potential clozapine-induced mania. In this case report and review, we present a 47-year-old caucasian male with a well-established history of schizophrenia who was voluntarily admitted to an inpatient psychiatric unit for paranoia and auditory hallucinations. The patient had trialed multiple antipsychotics prior to the current hospitalization, with the exception of clozapine. To our knowledge, this is the second case report of manic-like symptoms that may be secondary to clozapine.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"56-59"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic Treatment of Autistic Shutdowns-A Case Study.","authors":"Kevin Colwell, Keenan Boianghu, Jillian Komornik, Susan Brown","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"66-70"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quetiapine and Paediatric Psychiatrica: <i>Evidence or Diffidence?</i>","authors":"Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"31-36"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Akinetic Mutism Following Bilateral Infarcts Associated with a Mitral Valve Papillary Fibroelastoma.","authors":"Stanley Lyndon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Akinetic mutism is a rare but important clinical syndrome characterised by a profound decrease in goal-directed behaviour and speech output, yet with preservation of consciousness. This report describes the case of a 58-year-old male with a background of hypertension, alcohol use disorder, smoking, and MTHFR C677T homozygosity who experienced two ischaemic strokes within weeks of each other. The initial infarct involved the right thalamus, posterior putamen, external capsule, and subcortical anterior frontal lobe. Approximately five weeks later, he developed a second stroke in the left hemisphere, eventually leading to the identification of a mitral valve mass consistent with a papillary fibroelastoma. Following surgical resection of this mass, the patient demonstrated severe reductions in spontaneous movement and speech in a pattern consistent with akinetic mutism. He ultimately improved with rehabilitative measures and the initiation of a stimulant medication. This case highlights the intricate relationship between bilateral frontal-subcortical network injuries and the development of akinetic mutism.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.","authors":"Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A Musso","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine, several series of electroconvulsive therapy (ECT), ketamine infusion (KET-IFU), compounded ketamine intranasal spray (COM-KET), and intranasal esketamine (ESK). She had seventeen documented hospitalizations, five self-reported hospitalizations, three intensive outpatient program treatments, two partial hospitalization program treatments, and three residential treatments. She attempted suicide seven times. She received five acute ECT series, one series of KET-IFU, one series of acute ESK with weekly ECT, a series of COM-KET treatment for more than two years, and a series of ESK for more than two years. The patient had some short-term benefit from ECT and KET-IFU. However, she had two-years stability with COM-KET or ESK at two different times. She has been relatively stable without hospitalization or suicide attempt with ESK for more than two years, suggesting that patients with TRD with complex representations may benefit from ketamine treatment at different times of life development.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"44-55"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incretin Mimetics (GLP-1 Agonists) as an Addition to the Psychopharmacology Armamentarium.","authors":"Hend Fm Fr Alenezi, Ahmed Naguy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The exploration of GLP-1 receptor agonists as pleiotropic agents in the treatment of neuropsychiatric disorders and substance use disorders is a rapidly evolving field. While early studies have shown promising results, much of the research is still nascent, and larger clinical trials are definitely needed to confirm the safety and efficacy of these agents on real grounds.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"26-30"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Outpatient Buprenorphine Prescribing for Chronic Pain: A Retrospective Analysis Over 18 Months.","authors":"Jamal Hasoon, Ahish Chitneni, Omar Viswanath, Ivan Urits, Farnad Imani, Giustino Varrassi","doi":"","DOIUrl":"","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Buprenorphine, a partial opioid agonist, has gained attention for its use in chronic pain management due to its lower risk of abuse and respiratory depression compared to traditional opioids. The utilization of buprenorphine for chronic pain has increased in recent years. This study aimed to analyze trends in buprenorphine prescribing for chronic pain in an outpatient setting over an 18-month period, excluding buprenorphine-naloxone combinations used for opioid use disorder and opioid dependence.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective chart review was conducted, examining outpatient buprenorphine and long-acting opioid prescriptions issued by three pain management physicians between January 1, 2023, and June 30, 2024. Prescription data were collected from electronic medical records (EMRs) and analyzed across three six-month intervals: January 1, 2023, to June 30, 2023; July 1, 2023, to December 31, 2023; and January 1, 2024, to June 30, 2024. Only unique buprenorphine prescriptions for chronic pain management were included, while buprenorphine-naloxone prescriptions for opioid use disorder were excluded. Long-acting opioids analyzed included extended release (ER) formulations including tramadol ER, morphine ER, hydrocodone ER, oxycodone ER, fentanyl, and methadone.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Over the 18-month study period, a total of 61 unique buprenorphine prescriptions for chronic pain were issued by the three physicians. The number of prescriptions increased across each six-month period: 18 prescriptions were issued between January 1, 2023, and June 30, 2023; 20 prescriptions from July 1, 2023, to December 31, 2023; and 23 prescriptions from January 1, 2024, to June 30, 2024. This represents a 27.8% increase over the entire 18-month period. During the same timeframe, 117 long-acting opioid prescriptions (excluding buprenorphine) were issued in the first six-month period, 121 prescriptions in the second period, and 108 prescriptions in the third period. Buprenorphine prescriptions accounted for 13.3% of all long-acting opioid prescriptions in the first period (18 out of 135 total prescriptions), 14.2% in the second period (20 out of 141 total prescriptions), and 17.6% in the third period (23 out of 131 total prescriptions). Notably, while the absolute number of buprenorphine prescriptions increased steadily, its proportion relative to total long-acting opioid prescriptions also grew over time.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The findings demonstrate a steady increase in buprenorphine prescribing for chronic pain in the outpatient setting, while long-acting opioid prescriptions exhibited a slight decline in the later periods. The proportion of buprenorphine prescriptions relative to long-acting opioids increased over time, suggesting growing acceptance of buprenorphine as a safer alternative for chronic pain management. Further research is needed to explore the factors driving these prescribing p","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"8-19"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges in Transitioning from Methadone to Buprenorphine-Naloxone for Chronic Pain Management: Two Cases.","authors":"Jamal Hasoon, Anvinh Nguyen, Omar Viswanath, Alaa Abd-Elsayed","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Methadone is frequently used for chronic pain management due to its long half-life and NMDA receptor activity, making it an effective option for opioid-tolerant patients. Buprenorphine-naloxone is increasingly explored as an alternative for chronic pain and opioid use disorder, offering partial opioid agonism with a ceiling effect on respiratory depression. The transition from methadone to buprenorphine-naloxone remains clinically challenging, requiring careful management to prevent withdrawal and ensure adequate pain control.</p><p><strong>Case descriptions: </strong>Two patients with chronic pain were transitioned from methadone to buprenorphine-naloxone. The first patient, a mid-40s female, was abruptly switched from methadone 10 mg twice daily dosing to buprenorphine-naloxone 4 mg-1 mg twice daily dosing without a taper, resulting in severe withdrawal requiring hospitalization. The second patient, a late-50s male, underwent a two-month methadone taper before initiating buprenorphine-naloxone 4 mg-1 mg twice daily dosing, but reported persistent uncontrolled pain despite dose escalation to 4 mg-1 mg three times a day. Both patients reported significant dissatisfaction with buprenorphine-naloxone therapy, citing inadequate pain relief. Both patients eventually left the practice and were lost to follow up.</p><p><strong>Conclusion: </strong>These cases underscore the challenges of transitioning chronic pain patients from methadone to buprenorphine-naloxone formulations. Transitioning patients between these medications may lead to issues regarding withdrawal symptoms, inadequate pain control, and patient attrition.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"60-65"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kuwait-Mental Illness Disability Scale (K-MIDS): <i>A Proposal</i>.","authors":"Bibi Alamiri, Hend Fm Fr Alenezi, Ahmed Naguy","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>It is widely agreed that the mentally ill constitute a sizeable chunk of the disabled population not only for those afflicted but also for their caregivers alike.</p><p><strong>Objective: </strong>To assess the degree of disability with subsequent medico-legal ramifications, clinicians largely rely on generic clinical impressions and short brief interviews that are by no means bias-free lacking in standardization and objectivity.</p><p><strong>Methods: </strong>To this end, authors, herein, draft, the K-MIDS or the Kuwait-Mental Illness Disability Scale.</p><p><strong>Results: </strong>Baseline Requirements and Scoring System of K-MIDS are devised largely drawing on authors' vast clinical expertise in this area.</p><p><strong>Conclusions: </strong>The assessment of functional disability related to serious mental illness remains an unmet need in the Gulf region where disability allowance is currently based on generic clinical impressions, brief interviews and collateral input. K-MIDS is intended to be a step moving forward. Psychometric properties are due second.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Correlation Between Unipolar and Bipolar Depression, Calcium Levels, Thyroid Function, and Inflammatory Markers: A Pilot Cross-Sectional Study.","authors":"Marta Ielmini, Daniela Gallo, Maria Laura Tanda, Eliana Piantanida, Camilla Callegari, Ivano Caselli","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Recent mental health research has highlighted the critical role of inflammation in conditions like depression and bipolar disorder, examining correlations with markers such as calcium levels, thyroid function, and inflammatory markers. The study aims to compare unipolar and bipolar depression samples in terms of socio-demographic and clinical features. Patients were prospectively enrolled during their hospitalization at the University of Insubria Psychiatric Unit. Patients were administered psychometric questionnaires (Beck Depression Inventory-II, Mental Pain Questionnaire, Beck Anxiety Inventory, Clinical Global Impressions Severity scale, and Brief Reasons for Living Inventory). Thirty-six patients (17 males, 19 females) were enrolled. A statistically significant association emerged between calcium levels and bipolar depression (Pearson Chi square = 0.050) and between CRP and bipolar depression (Pearson Chi-square = 0.017). Additionally, a statistically significant association was observed between the unipolar and bipolar depression subgroups and current substance abuse (p = 0.0275) A statistically significant difference between the BRLF scores and UD (unipolar depression) subgroup emerged (p = 0.0126). The results of the pilot study revealed significant associations between calcium/CRP levels with depressive symptoms, particularly in bipolar depression. Further research on inflammatory markers is needed to refine diagnostic subtypes and therapeutic strategies.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 2","pages":"8-23"},"PeriodicalIF":0.0,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}